Table 1.
Phenotype | Number of patients | GSTM1‐null/present genotype | P a | |||
---|---|---|---|---|---|---|
Null | Present | |||||
N | % | N | % | |||
Age | ||||||
≤45 y | 248 | 139 | 56 | 109 | 44 | .94 |
>45 y | 466 | 259 | 56 | 207 | 44 | |
Lymph node | ||||||
Negative | 405 | 228 | 56 | 177 | 44 | .73 |
Positive | 309 | 170 | 55 | 139 | 45 | |
Size | ||||||
≤2 cm | 399 | 229 | 57 | 170 | 43 | .32 |
>2 cm | 315 | 169 | 54 | 146 | 46 | |
IHC‐based subtype | ||||||
HR+HER2− | 415 | 228 | 55 | 187 | 45 | .49 |
HR+HER2+ | 85 | 54 | 64 | 31 | 36 | |
HR‐HER2− | 134 | 72 | 54 | 62 | 46 | |
HR‐HER2+ | 80 | 44 | 55 | 36 | 45 | |
Chemotherapy | ||||||
No | 213 | 119 | 56 | 94 | 44 | .96 |
Yes | 501 | 279 | 56 | 222 | 44 |
HR, hormone receptor; IHC, immunohistochemistry.
χ2 tested P values for heterogeneity.